MediWound commences Phase III trial for venous leg ulcers treatment
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
health.economictimes.indiatimes2d
MediWound to launch Phase III trial for venous leg ulcers
The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...
MediWound begins pivotal Phase III trial for wound therapy
YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...
MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...
Healio4d
Novel device for meibomian gland debridement safe, effective in dry eye treatment
A new device for meibomian gland debridement was safe and effective and demonstrated time and space benefits compared with conventional debridement and expression approaches, according to a study ...